Undoctored vault view

Bayer has announced that from 1 June, EYLEA® (aflibercept) will be accessible as the second-line treatment option for Wet Age Related Macular Degeneration (wet-AMD) and Diabetic Macular Oedema (DMO) and will be made available in both hospitals and the community. PHARMAC funding was granted earlier this month and is expected to benefit around 900 people in its first year.¹

The Labour-led Government’s first Budget shows promise, the PSA says - but there are still many in the public and community service who will wonder when their turn is coming

Thousands of New Zealanders will benefit from advances in treatment as a result of two PHARMAC funding decisions

The Pharmacy Council of New Zealand has regretfully received the resignation of Deputy Chair, Leanne Te Karu. Chair, Mark Bedford, has sincerely thanked Leanne for her immense contribution over a seven-year period and has commended her for being a role model for the profession.

University of Auckland academics have developed new equations to predict the risk of cardiovascular disease (mainly heart attacks and strokes) in New Zealanders that has just been published in the prestigious medical journal The Lancet.

New Zealand’s Douglas Pharmaceuticals has entered a new collaboration with The University of Western Australia building on the work of researchers from UWA and the Telethon Kids Institute, to develop immunotherapy treatments for cancer.

ACC will fund a free, independent service to help clients navigate our processes, or to better understand or dispute a decision

Net sales for the nine months to 31 March of $434 million, up 8.5% compared to prior corresponding period